An interventional study of Transcutaneous electrical acupoint stimulation and Sham stimulation in Hypertension, sponsored by Shanghai Jiao Tong University School of Medicine. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-15.
Sponsored by Shanghai Jiao Tong University School of Medicine · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Hypertension by Shanghai Jiao Tong University School of Medicine — 6 open to participants now, 7 under way, none of them phase 3. Hypertension · Shanghai Jiao Tong University School of Medicine.
Among the 15 studies in Hypertension by Shanghai Jiao Tong University School of Medicine, this one is the 10th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2025, is one of 4 with no phase, and was the 13th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →6 of the 15 studies in Hypertension by Shanghai Jiao Tong University School of Medicine are open now, in 1 country. Recruiting first, the newest first:
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18+
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18+
Shanghai Jiao Tong University School of Medicine · Sites in China
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–80
Shanghai Jiao Tong University School of Medicine
Ages 65–84 · Men only · Healthy volunteers
By country, each count listing its studies:
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 320 across the 13 interventional studies, 567 across the 2 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Shanghai Jiao Tong University School of Medicine is the lead sponsor of 374 studies on the registry; 110 are open to participants now.
4 of the studies in Hypertension by Shanghai Jiao Tong University School of Medicine that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05735444Shanghai Jiao Tong University School of MedicineProspective National Multi-center Registry of Obstructive Sleep Apnea Syndrome in Hypertensive Patients in China | 2026-12 |
| NCT06790927Shanghai Jiao Tong University School of MedicineStandardized Antihypertensive Treatment Protocol | 2026-12-31 |
| NCT05363748Shanghai Jiao Tong University School of MedicineRenal Artery Fibromuscular Dysplasia Registry | 2026-12-31 |
| NCT05530083Shanghai Jiao Tong University School of MedicineGroup Education Helps Smoking Cessation and Hypertension Control | 2027-01-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 15 studies in Hypertension by Shanghai Jiao Tong University School of Medicine, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will be conducted in patients with high-normal blood pressure and grade 1 hypertension and will be divided into two phases.
In Phase One, a small group of patients will undergo transcutaneous electrical acupoint stimulation treatment for three consecutive days. Blood pressure changes will be observed before and after each stimulation session, as well as 1 hour, 3 hours, and 5 hours after stimulation, during the night of the treatment day, and the next morning.
Phase Two will be a single-center, single-blind, parallel randomized controlled trial. After screening, patients will be randomly assigned to either the "stimulation" experimental group or the "sham stimulation" control group. For three consecutive days, both groups will receive their respective interventions at the same time each day, and their blood pressure changes will be recorded.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Transcutaneous electrical acupoint stimulation
Device: Sham stimulation
Participants will receive proper transcutaneous electrical acupoint stimulation treatment for three consecutive days. Each day, the selected five target acupoints (Renying, Quchi, Taichong, Zusanli, and Hegu) will be stimulated in rotation. Each acupoint will be stimulated once a day for 10 minutes, with a 2-minute interval between each acupoint, totaling 60 minutes. Throughout the trial, the stimulation parameters for each participant will remain constant, and the treatment will begin between 8:00 and 10:00 AM each day.
Participants will receive sham stimulation treatment, where the left-side skin near the selected five target acupoints (avoiding other functional acupoints) will be stimulated in rotation. The stimulation time and method will be the same as in the experimental group. Throughout the trial, the stimulation parameters for each participant will remain constant, and the treatment will begin between 8:00 and 10:00 AM each day.
Change in office systolic blood pressure between the third day after TEAS treatment and the baseline (before the start of treatment on the first day)
Time frame: At the third day after TEAS treatment and the baseline (before the start of treatment on the first day)
Changes in office systolic blood pressure at other time points before and after treatment
Time frame: At all other time points (excluding the third day after treatment) and the baseline (before the start of treatment on the first day)
Changes in office diastolic blood pressure at various time points before and after treatment
Time frame: At each time point before and after treatment and the baseline (before the start of treatment on the first day).
Changes in ambulatory blood pressure before and after treatment
Time frame: At the third day after the end of treatment and the baseline (before the start of treatment on the first day)
Changes in Hamilton Scale scores before and after treatment
Time frame: At the third day after the end of treatment and the baseline (before the start of treatment on the first day)
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Aug 2025; primary completion for Dec 2027, 28 months later.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 28 months is above that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Jiao Tong University School of Medicine →